Health care resource utilization and burden of disease in a U.S. Medicare population with a principal diagnosis of osteoarthritis of the knee

Journal of Medical Economics. doi: 10.1080/13696998.2020.1801453

Fang Chen, Wenqing Su, Angela V. Bedenbaugh & Arman Oruc

Lorecivivint, a Novel Intra‐articular CLK/DYRK1A Inhibitor and Wnt Pathway Modulator for Treatment of Knee Osteoarthritis: A Phase 2 Randomized Trial

Arthritis & Rheumatology. doi: 10.1002/art.41315

Yusuf Yazici, Timothy E. McAlindon, Allan Gibofsky, Nancy E. Lane, Daniel Clauw, Morgan Jones, John Bergfeld, Christopher J. Swearingen, Anita DiFrancesco, Ismail Simsek, Jeyanesh Tambiah, Marc C. Hochberg

A Small-Molecule Inhibitor of the Wnt Pathway, Lorecivivint (SM04690), as a Potential Disease-Modifying Agent for the Treatment of Degenerative Disc Disease

The Spine Journal. doi: 10.1016/j.spinee.2020.04.024

Vishal Deshmukh, PhD, Maureen Ibanez, MS, Haide Hu, PhD, Joseph Cahiwat, Ying Wei, MD, Joshua Stewart, BS, John Hood, PhD, Yusuf Yazici, MD